BIIB Biogen
- Official Name: BIOGEN INC.
- Headquarters: 225 Binney Street, CAMBRIDGE, MA, 02142 US
- CEO: Christopher Viehbacher
- Website: biogen.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Won by 0.199 | (2.871) - (3.070) | ||
| 2025-07-18 | 1 | Lost by 6.858 | (5.609) - 1.249 | ||
| 2025-07-25 | 2 | Lost by 5.743 | 4.549 - 10.292 | ||
| 2025-07-29 | 2R | Lost by 2.129 | (1.652) - 0.477 | ||
| 2025-08-01 | 3 | Won by 6.740 | 0.635 - (6.105) | ||
| 2025-08-07 | 1R | Won by 0.254 | (1.225) - (1.479) | ||
| 2025-08-08 | 4 | Lost by 14.390 | 1.196 - 15.586 | ||
| 2025-08-15 | 5 | Lost by 1.151 | 5.113 - 6.264 | ||
| 2025-08-21 | 2R | Lost by 0.219 | 0.103 - 0.322 | ||
| 2025-08-22 | 6 | Lost by 0.017 | 1.483 - 1.500 | ||
| 2025-08-29 | 7 | Lost by 2.894 | (5.096) - (2.202) | ||
| 2025-09-05 | 8 | Won by 8.761 TOTW | 5.971 - (2.790) | ||
| 2025-09-12 | 9 | Won by 3.263 TOTW | 3.224 - (0.039) | ||
| 2025-09-19 | 10 | Lost by 4.358 | (1.568) - 2.790 | ||
| 2025-09-26 | 11 | Lost by 2.680 | (3.463) - (0.783) | ||
| 2025-10-03 | 12 | Won by 15.386 | 13.959 - (1.427) | ||
| 2025-10-10 | 13 | Lost by 4.077 | (8.310) - (4.233) | ||
| 2025-10-17 | 14 | Lost by 2.433 | (2.474) - (0.041) | ||
| 2025-10-24 | 15 | Lost by 2.567 | 5.084 - 7.651 |
Latest News

A kidney transplant milestone has Wall Street excited about Biogen
JPMorgan strongly reset its price target on the company’s attractive 2027 pipeline catalysts.

Another Biotech IPO Pops on Rough Day for Broader Market
It's another risk-off day for the broader market, with tech taking another tumble, thanks to a continued slide for semiconductor stocks.

Biogen-backed Estuary nabs $93M for kidney disease gene therapy
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorde...

Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimerâs revenue growth, and key risk/reward driversâread now. Cli...
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform

Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), ann...

Biogen’s Quarterly Earnings Preview: What You Need to Know
Biogen is set to report its Q3 results soon, with analysts expecting a sharp double-digit decline in EPS.

Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the ...

Biogen (BIIB) Stock Is Up, What You Need To Know
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with...

Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom
Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or ...